Literature DB >> 30928438

PTEN Mutations Trigger Resistance to Immunotherapy.

Feixiong Cheng1, Charis Eng2.   

Abstract

Immune checkpoint-blocking antibodies are actively used to treat multiple cancer types; however, the underlying resistance mechanism remains unclear. In a recent study, Zhao et al. (Nat. Med. 2019;25:462-469) found that somatic PTEN mutations were associated with resistance to immune checkpoint inhibitors by altering immunosuppressive environments in patients with glioblastomas.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  PTEN; combination therapy; glioblastomas; immune checkpoint; immunotherapy resistance

Mesh：

Substances：

Year:  2019        PMID： 30928438     DOI： 10.1016/j.molmed.2019.03.003

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN： 1471-4914            Impact factor:   11.951


  9 in total

Review 1.  Clinical implications of mismatch repair deficiency in prostate cancer.

Authors:  Ramy Sedhom; Emmanuel S Antonarakis
Journal:  Future Oncol       Date:  2019-06-25       Impact factor: 3.404

2.  Conjugation of glucosylated polymer chains to checkpoint blockade antibodies augments their efficacy and specificity for glioblastoma.

Authors:  Tao Yang; Yuki Mochida; Xueying Liu; Hang Zhou; Jinbing Xie; Yasutaka Anraku; Hiroaki Kinoh; Horacio Cabral; Kazunori Kataoka
Journal:  Nat Biomed Eng       Date:  2021-10-11       Impact factor: 25.671

Review 3.  Toward Systems Pathology for PTEN Diagnostics.

Authors:  Nahal Haddadi; Glena Travis; Najah T Nassif; Ann M Simpson; Deborah J Marsh
Journal:  Cold Spring Harb Perspect Med       Date:  2020-05-01       Impact factor: 6.915

Review 4.  Emerging role of PTEN loss in evasion of the immune response to tumours.

Authors:  Thiago Vidotto; Camila Morais Melo; Erick Castelli; Madhuri Koti; Rodolfo Borges Dos Reis; Jeremy A Squire
Journal:  Br J Cancer       Date:  2020-04-24       Impact factor: 7.640

Review 5.  PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around.

Authors:  Anastasios Gkountakos; Giulia Sartori; Italia Falcone; Geny Piro; Ludovica Ciuffreda; Carmine Carbone; Giampaolo Tortora; Aldo Scarpa; Emilio Bria; Michele Milella; Rafael Rosell; Vincenzo Corbo; Sara Pilotto
Journal:  Cancers (Basel)       Date:  2019-08-09       Impact factor: 6.639

6.  Stereotactic body radiotherapy-induced abscopal effect twice after pembrolizumab failure in hereditary leiomyomatosis and renal cell carcinoma: a case report with genetic and immunologic analysis.

Authors:  Xinyue Zhang; Yijun Zhang; Yang Liu; Yuanzhong Yang; Pei Dong; Liru He; Fangjian Zhou
Journal:  Transl Androl Urol       Date:  2021-11

7.  Deep Learning Radiomics to Predict PTEN Mutation Status From Magnetic Resonance Imaging in Patients With Glioma.

Authors:  Hongyu Chen; Fuhua Lin; Jinming Zhang; Xiaofei Lv; Jian Zhou; Zhi-Cheng Li; Yinsheng Chen
Journal:  Front Oncol       Date:  2021-10-04       Impact factor: 6.244

Review 8.  Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review.

Authors:  Yolla Haibe; Ziad El Husseini; Rola El Sayed; Ali Shamseddine
Journal:  Int J Mol Sci       Date:  2020-08-27       Impact factor: 5.923

9.  Targeting the NANOG/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating the antitumor immunity cycle.

Authors:  Se Jin Oh; Hyo-Jung Lee; Kwon-Ho Song; Suyeon Kim; Eunho Cho; Jaeyoon Lee; Marcus W Bosenberg; Tae Woo Kim
Journal:  J Clin Invest       Date:  2022-03-15       Impact factor: 14.808
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.